TY - JOUR AU - Brook, J. PY - 1995 DA - 1995// TI - Fluorouracil and low-dose leucovorin versus fluorouracil and high-dose leucovorin: what is the real cost? What is the answer? JO - J Clin Oncol VL - 13 ID - Brook1995 ER - TY - JOUR AU - de Gramont, A. AU - Bosset, J. F. AU - Milan, C. AU - Rougier, P. AU - Bouche, O. AU - Etienne, P. L. AU - Morvan, F. AU - Louvet, C. AU - Guillot, T. AU - Francois, E. PY - 1997 DA - 1997// TI - Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study JO - J Clin Oncol VL - 15 ID - de Gramont1997 ER - TY - JOUR AU - de Gramont, A. AU - Figer, A. AU - Seymour, M. AU - Homerin, M. AU - Hmissi, A. AU - Cassidy, J. AU - Boni, C. AU - Cortes-Funes, H. AU - Cervantes, A. AU - Freyer, G. PY - 2000 DA - 2000// TI - Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer JO - J Clin Oncol VL - 18 ID - de Gramont2000 ER - TY - JOUR AU - Douillard, J. Y. AU - Cunningham, D. AU - Roth, A. D. AU - Navarro, M. AU - James, R. D. AU - Karasek, P. AU - Jandik, P. AU - Iveson, T. AU - Carmichael, J. AU - Alakl, M. PY - 2000 DA - 2000// TI - Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial JO - Lancet VL - 355 UR - https://doi.org/10.1016/S0140-6736(00)02034-1 DO - 10.1016/S0140-6736(00)02034-1 ID - Douillard2000 ER - TY - JOUR AU - Tournigand, C. AU - Andre, T. AU - Achille, E. AU - Lledo, G. AU - Flesh, M. AU - Mery-Mignard, D. AU - Quinaux, E. AU - Couteau, C. AU - Buyse, M. AU - Ganem, G. PY - 2004 DA - 2004// TI - FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.05.113 DO - 10.1200/JCO.2004.05.113 ID - Tournigand2004 ER - TY - JOUR AU - Ferrara, N. PY - 1999 DA - 1999// TI - Molecular and biological properties of vascular endothelial growth factor JO - J Mol Med VL - 77 UR - https://doi.org/10.1007/s001099900019 DO - 10.1007/s001099900019 ID - Ferrara1999 ER - TY - JOUR AU - Presta, L. G. AU - Chen, H. AU - O'Connor, S. J. AU - Chisholm, V. AU - Meng, Y. G. AU - Krummen, L. AU - Winkler, M. AU - Ferrara, N. PY - 1997 DA - 1997// TI - Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders JO - Cancer Res VL - 57 ID - Presta1997 ER - TY - JOUR AU - Hurwitz, H. AU - Fehrenbacher, L. AU - Novotny, W. AU - Cartwright, T. AU - Hainsworth, J. AU - Heim, W. AU - Berlin, J. AU - Baron, A. AU - Griffing, S. AU - Holmgren, E. PY - 2004 DA - 2004// TI - Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa032691 DO - 10.1056/NEJMoa032691 ID - Hurwitz2004 ER - TY - JOUR AU - Bir, A. AU - Tan, W. AU - Wilding, G. E. AU - Lombardo, J. AU - Fakih, M. G. PY - 2007 DA - 2007// TI - 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study JO - Oncology VL - 72 UR - https://doi.org/10.1159/000110546 DO - 10.1159/000110546 ID - Bir2007 ER - TY - JOUR AU - Emmanouilides, C. AU - Sfakiotaki, G. AU - Androulakis, N. AU - Kalbakis, K. AU - Christophylakis, C. AU - Kalykaki, A. AU - Vamvakas, L. AU - Kotsakis, A. AU - Agelaki, S. AU - Diamandidou, E. PY - 2007 DA - 2007// TI - Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study JO - BMC Cancer VL - 7 UR - https://doi.org/10.1186/1471-2407-7-91 DO - 10.1186/1471-2407-7-91 ID - Emmanouilides2007 ER - TY - JOUR AU - Giantonio, B. J. AU - Levy, D. E. AU - O'Dwyer, P. J. AU - Meropol, N. J. AU - Catalano, P. J. AU - Benson, A. B. PY - 2006 DA - 2006// TI - A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200 JO - Ann Oncol VL - 17 UR - https://doi.org/10.1093/annonc/mdl161 DO - 10.1093/annonc/mdl161 ID - Giantonio2006 ER - TY - JOUR AU - Grothey, E. AU - Chu, E. PY - 2007 DA - 2007// TI - The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer JO - Clin Colorectal Cancer VL - 6 UR - https://doi.org/10.1016/S1533-0028(11)70301-2 DO - 10.1016/S1533-0028(11)70301-2 ID - Grothey2007 ER - TY - JOUR AU - Gruenberger, B. AU - Tamandl, D. AU - Schueller, J. AU - Scheithauer, W. AU - Zielinski, C. AU - Herbst, F. AU - Gruenberger, T. PY - 2008 DA - 2008// TI - Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.13.7679 DO - 10.1200/JCO.2007.13.7679 ID - Gruenberger2008 ER - TY - JOUR AU - Hurwitz, H. I. AU - Fehrenbacher, L. AU - Hainsworth, J. D. AU - Heim, W. AU - Berlin, J. AU - Holmgren, E. AU - Hambleton, J. AU - Novotny, W. F. AU - Kabbinavar, F. PY - 2005 DA - 2005// TI - Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.10.017 DO - 10.1200/JCO.2005.10.017 ID - Hurwitz2005 ER - TY - JOUR AU - Giantonio, B. J. AU - Catalano, P. J. AU - Meropol, N. J. AU - O'Dwyer, P. J. AU - Mitchell, E. P. AU - Alberts, S. R. AU - Schwartz, M. A. AU - Benson, A. B. PY - 2007 DA - 2007// TI - Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.6305 DO - 10.1200/JCO.2006.09.6305 ID - Giantonio2007 ER - TY - JOUR AU - Potter, C. P. AU - Harris, A. L. PY - 2003 DA - 2003// TI - Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer JO - Br J Cancer VL - 89 UR - https://doi.org/10.1038/sj.bjc.6600936 DO - 10.1038/sj.bjc.6600936 ID - Potter2003 ER - TY - JOUR AU - Robertson, N. AU - Potter, C. AU - Harris, A. L. PY - 2004 DA - 2004// TI - Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion JO - Cancer Res VL - 64 UR - https://doi.org/10.1158/0008-5472.CAN-03-2224 DO - 10.1158/0008-5472.CAN-03-2224 ID - Robertson2004 ER - TY - JOUR AU - Pastorekova, S. AU - Zavadova, Z. AU - Kostal, M. AU - Babusikova, O. AU - Zavada, J. PY - 1992 DA - 1992// TI - A novel quasi-viral agent, MaTu, is a two-component system JO - Virology VL - 187 UR - https://doi.org/10.1016/0042-6822(92)90464-Z DO - 10.1016/0042-6822(92)90464-Z ID - Pastorekova1992 ER - TY - JOUR AU - Saarnio, J. AU - Parkkila, S. AU - Parkkila, A. K. AU - Haukipuro, K. AU - Pastorekova, S. AU - Pastorek, J. AU - Kairaluoma, M. I. AU - Karttunen, T. J. PY - 1998 DA - 1998// TI - Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation JO - The American journal of pathology VL - 153 UR - https://doi.org/10.1016/S0002-9440(10)65569-1 DO - 10.1016/S0002-9440(10)65569-1 ID - Saarnio1998 ER - TY - JOUR AU - Therasse, P. AU - Arbuck, S. G. AU - Eisenhauer, E. A. AU - Wanders, J. AU - Kaplan, R. S. AU - Rubinstein, L. AU - Verweij, J. AU - Van Glabbeke, M. AU - van Oosterom, A. T. AU - Christian, M. C. PY - 2000 DA - 2000// TI - New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada JO - J Natl Cancer Inst VL - 92 UR - https://doi.org/10.1093/jnci/92.3.205 DO - 10.1093/jnci/92.3.205 ID - Therasse2000 ER - TY - JOUR AU - Karapetis, C. S. AU - Khambata-Ford, S. AU - Jonker, D. J. AU - O'Callaghan, C. J. AU - Tu, D. AU - Tebbutt, N. C. AU - Simes, R. J. AU - Chalchal, H. AU - Shapiro, J. D. AU - Robitaille, S. PY - 2008 DA - 2008// TI - K-ras mutations and benefit from cetuximab in advanced colorectal cancer JO - The New England journal of medicine VL - 359 UR - https://doi.org/10.1056/NEJMoa0804385 DO - 10.1056/NEJMoa0804385 ID - Karapetis2008 ER - TY - JOUR AU - Winum, J. Y. AU - Rami, M. AU - Scozzafava, A. AU - Montero, J. L. AU - Supuran, C. PY - 2008 DA - 2008// TI - Carbonic anhydrase IX: a new druggable target for the design of antitumor agents JO - Med Res Rev VL - 28 UR - https://doi.org/10.1002/med.20112 DO - 10.1002/med.20112 ID - Winum2008 ER - TY - JOUR AU - Selvakumaran, M. AU - Yao, K. S. AU - Feldman, M. D. AU - O'Dwyer, P. J. PY - 2008 DA - 2008// TI - Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis JO - Biochem Pharmacol VL - 75 UR - https://doi.org/10.1016/j.bcp.2007.09.029 DO - 10.1016/j.bcp.2007.09.029 ID - Selvakumaran2008 ER - TY - JOUR AU - Swietach, P. AU - Vaughan-Jones, R. D. AU - Harris, A. L. PY - 2007 DA - 2007// TI - Regulation of tumor pH and the role of carbonic anhydrase 9 JO - Cancer Metastasis Rev VL - 26 UR - https://doi.org/10.1007/s10555-007-9064-0 DO - 10.1007/s10555-007-9064-0 ID - Swietach2007 ER - TY - JOUR AU - Lee, J. C. AU - Chow, N. H. AU - Wang, S. T. AU - Huang, S. M. PY - 2000 DA - 2000// TI - Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients JO - Eur J Cancer VL - 36 UR - https://doi.org/10.1016/S0959-8049(00)00003-4 DO - 10.1016/S0959-8049(00)00003-4 ID - Lee2000 ER - TY - JOUR AU - Jubb, A. M. AU - Hurwitz, H. I. AU - Bai, W. AU - Holmgren, E. B. AU - Tobin, P. AU - Guerrero, A. S. AU - Kabbinavar, F. AU - Holden, S. N. AU - Novotny, W. F. AU - Frantz, G. D. PY - 2006 DA - 2006// TI - Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.01.5388 DO - 10.1200/JCO.2005.01.5388 ID - Jubb2006 ER - TY - JOUR AU - Lee, S. AU - Shin, H. J. AU - Han, I. O. AU - Hong, E. K. AU - Park, S. Y. AU - Roh, J. W. AU - Shin, K. H. AU - Kim, T. H. AU - Kim, J. Y. PY - 2007 DA - 2007// TI - Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer JO - Cancer Sci VL - 98 UR - https://doi.org/10.1111/j.1349-7006.2007.00396.x DO - 10.1111/j.1349-7006.2007.00396.x ID - Lee2007 ER - TY - JOUR AU - Giatromanolaki, A. AU - Koukourakis, M. I. AU - Sivridis, E. AU - Pastorek, J. AU - Wykoff, C. C. AU - Gatter, K. C. AU - Harris, A. L. PY - 2001 DA - 2001// TI - Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer JO - Cancer Res VL - 61 ID - Giatromanolaki2001 ER - TY - JOUR AU - Brennan, D. J. AU - Jirstrom, K. AU - Kronblad, A. AU - Millikan, R. C. AU - Landberg, G. AU - Duffy, M. J. AU - Ryden, L. AU - Gallagher, W. M. AU - O'Brien, S. L. PY - 2006 DA - 2006// TI - CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-06-0480 DO - 10.1158/1078-0432.CCR-06-0480 ID - Brennan2006 ER - TY - JOUR AU - Choi, S. W. AU - Kim, J. Y. AU - Park, J. Y. AU - Cha, I. H. AU - Kim, J. AU - Lee, S. PY - 2008 DA - 2008// TI - Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma JO - Hum Pathol VL - 39 UR - https://doi.org/10.1016/j.humpath.2007.10.026 DO - 10.1016/j.humpath.2007.10.026 ID - Choi2008 ER - TY - JOUR AU - Atkins, M. AU - Regan, M. AU - McDermott, D. AU - Mier, J. AU - Stanbridge, E. AU - Youmans, A. AU - Febbo, P. AU - Upton, M. AU - Lechpammer, M. AU - Signoretti, S. PY - 2005 DA - 2005// TI - Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-04-2019 DO - 10.1158/1078-0432.CCR-04-2019 ID - Atkins2005 ER - TY - JOUR AU - Bui, M. H. AU - Seligson, D. AU - Han, K. R. AU - Pantuck, A. J. AU - Dorey, F. J. AU - Huang, Y. AU - Horvath, S. AU - Leibovich, B. C. AU - Chopra, S. AU - Liao, S. Y. PY - 2003 DA - 2003// TI - Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy JO - Clin Cancer Res VL - 9 ID - Bui2003 ER - TY - JOUR AU - Uemura, H. AU - Nakagawa, Y. AU - Yoshida, K. AU - Saga, S. AU - Yoshikawa, K. AU - Hirao, Y. AU - Oosterwijk, E. PY - 1999 DA - 1999// TI - MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas JO - British journal of cancer VL - 81 UR - https://doi.org/10.1038/sj.bjc.6690757 DO - 10.1038/sj.bjc.6690757 ID - Uemura1999 ER - TY - JOUR AU - Leibovich, B. C. AU - Sheinin, Y. AU - Lohse, C. M. AU - Thompson, R. H. AU - Cheville, J. C. AU - Zavada, J. AU - Kwon, E. D. PY - 2007 DA - 2007// TI - Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2007.12.1087 DO - 10.1200/JCO.2007.12.1087 ID - Leibovich2007 ER - TY - JOUR AU - Sathornsumetee, S. AU - Cao, Y. AU - Marcello, J. E. AU - Herndon, J. E. AU - McLendon, R. E. AU - Desjardins, A. AU - Friedman, H. S. AU - Dewhirst, M. W. AU - Vredenburgh, J. J. AU - Rich, J. N. PY - 2008 DA - 2008// TI - Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.13.3652 DO - 10.1200/JCO.2007.13.3652 ID - Sathornsumetee2008 ER - TY - JOUR AU - Vredenburgh, J. J. AU - Desjardins, A. AU - Herndon, J. E. AU - Dowell, J. M. AU - Reardon, D. A. AU - Quinn, J. A. AU - Rich, J. N. AU - Sathornsumetee, S. AU - Gururangan, S. AU - Wagner, M. PY - 2007 DA - 2007// TI - Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-2309 DO - 10.1158/1078-0432.CCR-06-2309 ID - Vredenburgh2007 ER - TY - JOUR AU - Relf, M. AU - LeJeune, S. AU - Scott, P. A. AU - Fox, S. AU - Smith, K. AU - Leek, R. AU - Moghaddam, A. AU - Whitehouse, R. AU - Bicknell, R. AU - Harris, A. L. PY - 1997 DA - 1997// TI - Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis JO - Cancer Res VL - 57 ID - Relf1997 ER - TY - JOUR AU - Johnson, D. H. AU - Fehrenbacher, L. AU - Novotny, W. F. AU - Herbst, R. S. AU - Nemunaitis, J. J. AU - Jablons, D. M. AU - Langer, C. J. AU - DeVore, R. F. AU - Gaudreault, J. AU - Damico, L. A. PY - 2004 DA - 2004// TI - Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.11.022 DO - 10.1200/JCO.2004.11.022 ID - Johnson2004 ER - TY - JOUR AU - Yang, J. C. AU - Haworth, L. AU - Sherry, R. M. AU - Hwu, P. AU - Schwartzentruber, D. J. AU - Topalian, S. L. AU - Steinberg, S. M. AU - Chen, H. X. AU - Rosenberg, S. A. PY - 2003 DA - 2003// TI - A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer JO - N Engl J Med VL - 349 UR - https://doi.org/10.1056/NEJMoa021491 DO - 10.1056/NEJMoa021491 ID - Yang2003 ER - TY - JOUR AU - Reck, M. AU - von Pawel, J. AU - Zatloukal, P. AU - Ramlau, R. AU - Gorbounova, V. AU - Hirsh, V. AU - Leighl, N. AU - Mezger, J. AU - Archer, V. AU - Moore, N. PY - 2009 DA - 2009// TI - Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2007.14.5466 DO - 10.1200/JCO.2007.14.5466 ID - Reck2009 ER - TY - JOUR AU - Kabbinavar, F. AU - Hurwitz, H. I. AU - Fehrenbacher, L. AU - Meropol, N. J. AU - Novotny, W. F. AU - Lieberman, G. AU - Griffing, S. AU - Bergsland, E. PY - 2003 DA - 2003// TI - Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.10.066 DO - 10.1200/JCO.2003.10.066 ID - Kabbinavar2003 ER - TY - JOUR AU - Chen, H. X. AU - Mooney, M. AU - Boron, M. AU - Vena, D. AU - Mosby, K. AU - Grochow, L. AU - Jaffe, C. AU - Rubinstein, L. AU - Zwiebel, J. AU - Kaplan, R. S. PY - 2006 DA - 2006// TI - Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301 JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.05.1573 DO - 10.1200/JCO.2005.05.1573 ID - Chen2006 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/246/prepub UR - http://www.biomedcentral.com/1471-2407/9/246/prepub ID - ref43 ER -